Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on gene therapies for rare and devastating diseases. The company has three clinical-stage ex vivo lentiviral vector (“LVV”) programs which include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces the production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency (“PKD”), a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has a clinical-stage in vivo adeno-associated virus (“AAV”) program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Rocket Pharma is headquartered in Cranbury, New Jersy, the US.
Headquarters
United States of America
Address
350 5th Ave Ste 7530, New York, 10118-7501
Website
www.rocketpharma.com
Telephone
1 646 4409100
No of Employees
268
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RCKT (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-10.7%
(2022 vs 2021)
Market Cap*
$2.1B
* As of and is in US$
Rocket Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| lentiviral vector |
| Adeno-associated virus Program |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company's Marketing Authorization Application was approved by the European Medicines Agency for RP-L102, its lentiviral vector-based investigational gene therapy for Fanconi Anemia. |
| 2023 | Others | In October, the company announced that the U.S. Food and Drug Administration accepted the biologics license application and granted Priority Review for RP-L201. |
| 2023 | Regulatory Approval | In May, the company received Food and Drug Administration on the global Phase 2 pivotal trial of RP-A501 for Danon disease. |
Competitor Comparison
| Key Parameters | Rocket Pharmaceuticals Inc | Portola Pharmaceuticals LLC | Fortress Biotech Inc | DMK Pharmaceuticals Corp | Beacon Therapeutics (USA) Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York | South San Francisco | Bay Harbor Islands | San Diego | Alachua |
| State/Province | New York | California | Florida | California | Florida |
| No. of Employees | 268 | 408 | 186 | 11 | 102 |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Roderick Wong | Chairman | Executive Board | 2018 | 46 |
| Gaurav Shah | Director; Chief Executive Officer | Executive Board | 2018 | 48 |
| Aaron Ondrey | Chief Financial Officer | Senior Management | 2024 | - |
| Kinnari Patel | Head - R&D; President; Chief Operating Officer | Senior Management | 2024 | 45 |
| Mayo Pujols | Chief Technology Officer; Executive Vice President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward